Chengdu Easton Biopharmaceuticals Co Ltd
SSE:688513

Watchlist Manager
Chengdu Easton Biopharmaceuticals Co Ltd Logo
Chengdu Easton Biopharmaceuticals Co Ltd
SSE:688513
Watchlist
Price: 36.36 CNY -0.87%
Market Cap: 6.4B CNY
Have any thoughts about
Chengdu Easton Biopharmaceuticals Co Ltd?
Write Note

Wall Street
Price Targets

Price Targets Summary
Chengdu Easton Biopharmaceuticals Co Ltd

Wall Street analysts forecast Chengdu Easton Biopharmaceuticals Co Ltd stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for Chengdu Easton Biopharmaceuticals Co Ltd is 42.76 CNY with a low forecast of 42.34 CNY and a high forecast of 44.01 CNY.

Lowest
Price Target
42.34 CNY
16% Upside
Average
Price Target
42.76 CNY
18% Upside
Highest
Price Target
44.01 CNY
21% Upside
Chengdu Easton Biopharmaceuticals Co Ltd Competitors:
Price Targets
AMRX
Amneal Intermediate Inc
17% Upside
DRREDDY
Dr Reddy's Laboratories Ltd
9% Upside
1666
Tong Ren Tang Technologies Co Ltd
26% Upside
NATCOPHARM
Natco Pharma Ltd
7% Downside
SUNPHARMA
Sun Pharmaceutical Industries Ltd
5% Upside
ROVI
Laboratorios Farmaceuticos ROVI SA
56% Upside
EMCURE
Emcure Pharmaceuticals Ltd
20% Upside
TLRY
Tilray Brands Inc
57% Upside

Revenue
Forecast

Revenue Estimate
Chengdu Easton Biopharmaceuticals Co Ltd

For the last 5 years the compound annual growth rate for Chengdu Easton Biopharmaceuticals Co Ltd's revenue is 8%. The projected CAGR for the next 3 years is 24%.

8%
Past Growth
24%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

Operating Income
Forecast

Operating Income Estimate
Chengdu Easton Biopharmaceuticals Co Ltd

For the last 5 years the compound annual growth rate for Chengdu Easton Biopharmaceuticals Co Ltd's operating income is 7%. The projected CAGR for the next 3 years is 22%.

7%
Past Growth
22%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

Net Income
Forecast

Net Income Estimate
Chengdu Easton Biopharmaceuticals Co Ltd

For the last 5 years the compound annual growth rate for Chengdu Easton Biopharmaceuticals Co Ltd's net income is 11%. The projected CAGR for the next 3 years is 22%.

11%
Past Growth
22%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

See Also

Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is Chengdu Easton Biopharmaceuticals Co Ltd's stock price target?
Price Target
42.76 CNY

According to Wall Street analysts, the average 1-year price target for Chengdu Easton Biopharmaceuticals Co Ltd is 42.76 CNY with a low forecast of 42.34 CNY and a high forecast of 44.01 CNY.

What is Chengdu Easton Biopharmaceuticals Co Ltd's Revenue forecast?
Projected CAGR
24%

For the last 5 years the compound annual growth rate for Chengdu Easton Biopharmaceuticals Co Ltd's revenue is 8%. The projected CAGR for the next 3 years is 24%.

What is Chengdu Easton Biopharmaceuticals Co Ltd's Operating Income forecast?
Projected CAGR
22%

For the last 5 years the compound annual growth rate for Chengdu Easton Biopharmaceuticals Co Ltd's operating income is 7%. The projected CAGR for the next 3 years is 22%.

What is Chengdu Easton Biopharmaceuticals Co Ltd's Net Income forecast?
Projected CAGR
22%

For the last 5 years the compound annual growth rate for Chengdu Easton Biopharmaceuticals Co Ltd's net income is 11%. The projected CAGR for the next 3 years is 22%.

Back to Top